The Partnership for Vivax Elimination (PAVE)
The goal of PAVE is to support countries in accelerating the elimination of P. vivax malaria.
PAVE supports countries in achieving their elimination goals through:
- working with National Malaria Programmes to identify optimal radical cure tool options and strategies for their given contexts to achieve higher patient coverage.
- generating and making available high-quality evidence on P. vivax case management that can be considered by national governments in making policy decisions and guiding implementation.
- advancing the development of quality-assured medicines and diagnostics for P. vivax.
PAVE consolidates its project work from multiple funders and is aligned with country partners and the World Health Organization (WHO) to accelerate progress. This project is led by Medicines for Malaria Venture (MMV) and PATH, in close partnership with Ministries of Health, country partners, and other not-for-profit organizations. PAVE combines investments from Unitaid, the Bill & Melinda Gates Foundation, the UK Foreign, Commonwealth and Development Office (FCDO) and MMV core funding, among others.